European Neuropsychopharmacology (v.16, #S4)

P.4.a.005 Should the duration requirement for generalized anxiety disorder be changed? - Evidence from the national comorbidity survey replication by H.U. Wittchen; R.C. Kessler; N. Brandenburg; M. Lane; P. Roy-Byrne; P.D. Stang; D.J. Stein (S450).

P.4.a.003 Aripiprazole augmentation of fluvoxamine in poor-insight obsessive-compulsive patients by F. Panigada; L. Liperi; F.F. Siliprandi; G. Blaser; M. Locatelli; E. Smeraldi; C. Insacco (S450).

P.4.a.006 A fixed dose study of the efficacy and safety of duloxetine for the treatment of generalised anxiety disorder by H. Koponen; C. Allgulander; Y.L. Pritchett; J. Erickson; M.J. Detke; S. Ball; J.M. Russell (S451).

P.4.a.008 A randomized placebo controlled trial of olanzapine in trichotillomania by M. Van Ameringen; C. Mancini; B. Patterson; M. Bennett; J. Oakman (S452).

P.3.f.002 The 5-HT6 receptor antagonists, SB271,046 and SB258,585, enhance social memory and cholinergic transmission in rats: a comparison with 5-HT1A receptor partial agonists by F. Loiseau; M.J. Millan; J.M. Rivet; A. Gobert; L. De Groote; D. Sicard; B. Di Cara; L. Cistarelli; R. Billiras; A. Dekeyne (S447-S448).

P.4.a.009 Developmental trajectories of anxiety disorders in offspring at high risk for panic disorder by J. Biederman; C. Petty; D. Hirshfeld-Becker; A. Henin; B. Henry; S.V. Faraone; J.F. Rosenbaum (S452-S453).

P.4.a.019 Serotonin reuptake inhibition and dopamine receptor antagonism together buffer the blood pressure response to stress in social anxiety disorder by S.J.C. Davies; S.D. Hood; S.V. Argyropoulos; D.A. Hince; K. Morris; D.J. Nutt; J. Potokar (S458).

P.4.a.022 Association study of limbic system-associated membrane protein gene polymorphisms in panic disorder by E. Maron; K. Koido; A. Must; A. Reimets; S. Köks; E. Vasar; V. Vasar; J. Shlik (S459-S460).

P.4.a.017 Impaired recognition of fearful faces in generalized social phobia by M.J. Garner; D.S. Baldwin; B.P. Bradley; K. Mogg (S457).

P.4.a.016 Alcohol consumption in first stages of panic disorder: relationships with symptoms and impairment by B. Rodríguez-Cabo; A. Herrán; M.L. Ramírez; M. Carrera; A. Ayestarán; D. Sierra-Biddle; F. Hoyuela; J.L. Vázquez-Barquero (S456-S457).

P.3.e.007 Risperidone oral solution, therapeutic possibility in treatment of acute and agitated psychotic patients by D. Lasic; G. Rubesa; G. Dodig; Z. Katavic; T. Glavina; M. Zuljan-Cvitanovic (S445-S446).

P.3.d.012 The response of clozapine on midbrain dopamine neurons depends on endogenous concentration of kynurenic acid by L. Schwieler; K.R. Linderholm; L.K. Nilsson; G. Engberg; S. Erhardt (S435-S436).

P.3.d.011 In vitro and in vivo characterization of glycine transporter type-1 by two inhibitors, Org-24461 and NFPS by B. Marko; G. Szabo; S. Udvari; M. Agoston; E. Szabo; Z. Juranyi; A. Egyed; P. Matyus; L.G. Harsing (S435).

P.3.d.013 Correlation between acute atypical antipsychotic treatment and cognitive functioning in first episode psychosis by P. Fusar-Poli; M. Broome; P. Matthiasson; J. Woolley; L. Valmaggia; P. Tabraham; L. Johns; E. Bramon; S. Williams; M. Brammer; P. McGuire (S436).

P.3.d.014 Anti-S100 antibodies ameliorate haloperidol-induced catalepsy and do not change the activity of haloperidol in apomorphine-induced stereotypy by J.L. Dugina; I.A. Kheifez; A.V. Martyushev-Poklad; T.A. Voronina; G.M. Molodavkin; O.I. Epstein; S.A. Sergeva (S436-S437).

P.3.d.006 Pharmacological profile of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist atypical antipsychotic by I. Gyertyán; B. Kiss; K. Sághy; I. Laszlovszky; A. Horváth; J. Laszy; É. Schmidt; G. Szabó; G. Domány; É. Ágai Csongor; K. Tihanyi; Z. Szombathelyi (S432).

P.3.d.016 Effects of aripiprazole/OPC-14597 on pharmacological models of psychosis in rats by R.E. Nordquist; M. Maco; C. Freichel; C. Riemer; W.P. Spooren (S438).

P.3.d.017 Effect of first generation antipsychotic treatment on oxidative stress markers in schizophrenia by A. Mechri; C. Fendri; L. Ben Othman; A. Mekhinini; A. Kerkeni; L. Gaha (S438).

P.3.e.002 Clinical evaluation of levopromazine (methotrimeprazine) as add-on therapy in fibromyalgia management by P. Morillas-Arques; C.M. Rodriguez-Lopez; J.S. Vilchez; J. Hidalgo; F. Rico-Villademoros; E.P. Calandre (S442-S443).

P.3.e.001 Impact of the obesity on the use of antipsychotic drugs in a Spanish adult population setting by A. Sicras Mainar; M. Blanca Tamayo; R. Navarro Artieda; J. Serrat Tarres; J. Rejas Gutierrez; J.R. Llopart Lopez (S442).

P.3.e.003 Dissociation of working memory from decision-making in schizophrenia by Y.S. Kweon; K.U. Lee; S.J. Lee; Y.T. Kim; S.H. Kim; S.H. Jeung; H.K. Lee; J.T. Lee (S443-S444).

P.3.e.005 Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study by R. Prikryl; L. Ustohal; T. Kasparek; H. Kucerova; E. Ceskova; S. Skotakova (S444-S445).

P.3.d.023 Efficacy of a psychoeducational program for weight loss in patients who have experienced weight gain during treatment with olanzapine by S. Castrogiovanni; M. Simoncini; N. Iovieno; D. Cecconi; G. Dell' Agnello; P. Donda; M. Quadrigli; A. Rossi; M. Mauri (S441-S442).

P.3.d.020 Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients by F. Duval; N. Chokmani; M.C. Mokrani; J. He; J.P. Macher (S440).

P.4.b.002 The central neuropeptide S system: expression, pharmacology and behavioural significance of neuropeptide S receptors by S.K. Leonard; E. Kouranova; C. Bender; J.E. Malberg; L.E. Schechter; B. Luo; B. Platt; L. Potestio; C.E. Beyer; S. Rosenzweig-Lipson; R.H. Ring (S460-S461).

P.5.a.009 Effects of long term treatment with cholinesterase inhibitors on sleep EEG in patients with dementia of Alzheimer and frontotemporal type by U.M. Hemmeter; R. Rocamora; A. Thum; M. Giesler; A. Haag; A. Becker; J.C. Krieg (S480-S481).

P.5.a.011 Efficacy and safety of donepezil in vascular dementia:results from the largest double-blind trial in vascular dementia patients by G. Roman; S. Black; D.R. Royall; I. Surick; D. Kumar; R. Schindler; H. Posner (S481-S482).

P.5.b.002 Magnetic resonance spectroscopy in patients with alcoholic dementia by H.J. Go; Y.H. Cheon; K. Ahn; Y.D. Kim; D. Kim (S482-S483).

P.5.a.004 Validity of the Korean version of the Mini-Cog by Y.M. Choi; D.W. Lee; J.Y. Lee (S477-S478).

P.5.a.005 Possible benefits of valproate addition to donepezil treatment in Alzheimer's disease by A. Borkowska; M. Tomaszewska; M. Wilkosc; W. Drozdz; A. Cichosz; J.K. Rybakowski (S478).

P.5.a.006 Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer's disease by M.G. Scordo; F. Varsaldi; M.G. Arena; M.L. Villa; G. Lombardi; F. Cordici; M.L. Dahl (S478-S479).

P.5.e.002 An open-label study of quetiapine for delirium by N. Maneeton; B. Maneeton; M. Srisurapanont (S487-S488).

P.5.e.001 Does pneumoconiosis lead to cognitive dysfunction? by W.K. Tang; C.M. Lum; G.S. Ungvari; H.F.K. Chiu (S487).

P.5.e.003 Association of Alzheimer type dementia with hospital complications and health resource utilization in acute institutionalization by A. Sicras Mainar; R. Navarro Artieda; M. Blanca Tamayo; J.R. Llopart Lopez; N. Muro Perea; J. Rejas Gutierrez (S488).

P.5.d.002 Phospholipase D activation as a possible apoptotic signal in ischemic astrocytes by M. Krzystanek; I. Krupka-Matuszczyk; H.I. Trzeciak; E. Krzystanek (S486-S487).

P.5.d.001 Neuronal electrical high frequency stimulation enhances GABA release from human neocortical slices by M. Mantovani; V. Van Velthoven; H. Fuellgraf; T.J. Feuerstein; A. Moser (S486).

P.5.b.005 Memantine rescues cholinergic neurons from the neurotoxic effects of β-amyloid (Aβ1-42) by C. Nyakas; R. Szabó; B. Penke; P.G.M. Luiten; P.K. Banerjee (S484).

P.5.b.006 Age-dependent changes in hippocampal glutamate levels parallel learning impairment in APP/PS1 transgenic mice by R. Minkeviciene; J. Ihalainen; T. Malm; V. Keksa-Goldsteine; N. Leguit; J. Glennon; P.K. Banerjee; H. Tanila (S484-S485).

P.4.f.003 EPIA -anxiety as a trait in Slovakia by A. Heretik; V. Novotny; A. Heretik; J. Pecenak; A. Ritomsky (S475-S476).

P.4.c.004 Psychopharmacological drugs, anxiety and stress in premature coronary syndromes by J. Irurita; M. Irurita; C. Deniz; M.T. Martinez Saavedra; B. Ania; L. Lopez y Juan; C. Culebras; J.M. Saavedra; R. Chirino; F. Sanchez (S466).

P.4.c.001 Adjunctive quetiapine for SRI-resistant obsessive compulsive disorder: a meta-analysis of three randomised controlled treatment trials by N.A. Fineberg; D.J. Stein; P. Carey; B. Vythilingum; T. Sivakumaran; S. Seedat; H. Westenberg; D. Denys; P. Premkumar (S464-S465).

P.4.b.005 Social housing in male mice - impact on experimental anxiety-related behaviour? by S.S. Arndt; M. Laarakker; R. Sommer; I. Lemmens; X. Fielmich; H.A. Van Lith; F. Ohl (S462).

P.4.d.002 Which factors predict placebo response in anxiety disorders and major depression? by D.J. Stein; D.S. Baldwin; O. Dolberg; N. Despiegel; B. Bandelow (S468).

P.4.e.005 The effect of acute tryptophan depletion on challenge induced anxiety in anxiety disorder patients is independent of a history of depression by S.D. Hood; S.V. Argyropoulos; S.J.C. Davies; D.A. Hince; C.J. Bell; D.J. Nutt; J. Potokar (S473-S474).

P.4.e.004 Trait stability and agoraphobia in a one year follow up panic disorder sample by F. Hoyuela; M. Carrera; M.M. Ramirez; B. Rodríguez-Cabo; A. Ayestarán; D. Sierra-Biddle; A. Herrán; J.L. Vázquez-Barquero (S472-S473).

P.4.e.002 Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression by B. Aouizerate; C. Martin-Guehl; E. Cuny; D. Guehl; H. Amieva; A. Benazzouz; C. Fabrigoule; M. Allard; A. Rougier; B. Bioulac; J. Tignol; P. Burbaud (S471-S472).

P.4.d.004 A comparison of the anxiolytic-like efficacy of mechanistically-distinct compounds in animal behavioural models by D.G. Smith; T.D. Wolinsky; B. Nugent; P. Poon; N. Moore; C. Sanchez; C.J. Swanson (S469).

P.4.d.006 Is early treatment affecting antiobsessional response in obsessive-compulsive disorder? by B. Dell'Osso; E. Mundo; A. Ceralli; M. Russo; A.C. Altamura (S470).

P.3.d.003 A cross-sectional study of adiponectin in patients with schizophrenia by L. Hanssens; M. DeHert; D. Van Eyck; M. Wampers; A. Scheen; J. Peuskens (S430-S431).

P.3.d.002 Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia? by O. Kelemen; O. Nagy; A. Máttyássy; I. Kiss; Z. Janka; S. Kéri (S430).

P.3.a.049 Amisulpride monotherapy for elderly non-demented patients with very-late-onset schizophrenia-like psychosis by C. Psarros; C.G. Theleritis; A. Politis; G.N. Papadimitriou; C.R. Soldatos (S391).

P.3.a.048 Insight in schizophrenia: clinical correlates and relationship to functioning by G.M. Gharabawi; C.A. Bossie; P. Bouhours; I. Turkoz; M. Kujawa (S390-S391).

P.3.b.001 Polymorphisms of dysbindin gene (DTNBP1) and schizophrenia in the Korean population by T.Y. Jun; W.M. Bahk; J.H. Chae; C.U. Pae; Y.E. Jung; B.W. Lee; S.K. Bang; Y.S. Woo (S391-S392).

P.3.b.003 Validation of visuospatial navigation as a measure of episodic memory in schizophrenia by P. Boyer; J.L. Phillips; L.J. Boulay; A. Labelle; A.A. Ledoux (S393).

P.3.a.046 Pseudophaeochromocytoma syndrome caused by clozapine therapy - a case report by T. Sobanski; G. Wagner; S. Schubert; I. Dafov (S389-S390).

P.3.a.044 Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia by X. Laqueille; S. Ghodhbane; F. Nacef; Z. Choubani; M. Nehdi; S. Douki; A. Dervaux (S388-S389).

P.3.b.004 Evidence of a cortical disinhibition in schizophrenia: a transcranial magnetic stimulation study by C. Ben Amor; A. Galinowski; B. Gueguen; M.C. Bourdel; J.P. Olie; S. Douki; M.O. Krebs (S393-S394).

P.3.b.005 TC-5619: an a 7 neuronal nicotinic receptor-selective agonist with the potential to treat schizophrenia by T.A. Hauser; M. Bencherif; P.M. Lippiello; K.G. Jordan; G.J. Gatto (S394).

P.3.c.004 Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough? by R. Van Winkel; M. DeHert; D. Van Eyck; L. Hanssens; M. Wampers; A. Scheen; J. Peuskens (S398).

P.3.c.005 Evaluation of the metabolic safety of aripiprazole by M. De Hert; D. Van Eyck; L. Hanssens; M. Wampers; A. Scheen; J. Peuskens (S399).

P.3.c.006 A pilot crossover study on QTc interval associated with olanzapine and risperidone by K.P. Su; C.L. Huang; H.B. Hsu; C.M. Pariante (S399-S400).

P.3.c.007 A well being programme (WSP) in severe mental illness. Reducing risk for physical ill-health: a post programme re-audit at 2 years by S. Smith; D. Yeomans; C.J. Bushe; C. Eriksson; T. Harrison; R. Holmes; L. Mynors-Wallace; H. Oatway; G. Sullivan (S400).

P.3.c.002 A hyperinsulimic euglycaemic clamp study investigating the in fluence of treatment with olanzapine or ziprasidone on glucose-metabolism in healthy subjects by J. Sacher; N. Mossaheb; N. Klein; C. Spindelegger; T. Geiss-Granadia; R. Lanzenberger; E. Lackner; C. Joukhadar; M. Mueller; S. Kasper (S397).

P.3.b.006 Relationship between glutathione peroxidase activity, glutathione and selenium levels in schizophrenic patients by A. Mechri; A. Mekhinini; L. Ben Othman; C. Fendri; L. Gaha; A. Kerkeni (S394-S395).

P.3.b.008 Oxidative stress and neurodevelopmental abnormalities in schizophrenia by A. Mechri; C. Fendri; H. Slama; L. Ben Othman; A. Kerkeni; L. Gaha (S395-S396).

P.3.a.040 Clinical symptomatology and long-term memory in schizophrenia by A.A. Ledoux; R. Westmacott; J.L. Phillips; P. Boyer (S386).

P.3.a.021 Examination of specific genetic aspects of the dopaminergic neurotransmission and neuronal plasticity in neurocognitive subgrouping of schizophrenia by I. Szendi; A. Juhász; G. Szekeres; C. Cimmer; G. Csifcsak; A.Z. Kovacs; A. Rimanoczy; G. Galsi; K. Boda; Z. Janka (S375-S376).

P.3.a.023 Infiuence of glycine on cognitive functions in schizophrenia by D. Strzelecki; J. Rabe-Jablonska (S376-S377).

P.3.a.020 Subgroups within schizophrenia differentiated by clinical and neurocognitive parameters by I. Szendi; C. Cimmer; G. Csifcsak; G. Szekeres; A.Z. Kovacs; G. Galsi; M. Racsmany; K. Boda; Z. Janka (S374-S375).

P.3.a.015 Elaboration on the association between urbanicity and schizophrenia by M. Shmushkevitz; M. Weiser; J. VanOs; A. Reichenberg; J. Rabinowitz; D. Nahon; E. Kravitz; G. Lubin; H.Y. Knobler; S. Noy; M. Davidson (S372).

P.3.a.017 Deficient inhibition of return (IOR) in unmedicated patients with schizophrenia, but not in patients in risk for psychosis by E. Gouzoulis-Mayfrank; M. Shemirani; S. Hajsamou; S. Ruhrmann; T. Schnell; J. Daumann; F. Schultze-Luther; B. Hoppmann; K. Heekeren; K. Schnell (S373).

P.3.a.027 In fluences of polymorphisms of beta adrenergic receptors in the psychopharmacological treatment of schizophrenia by I. Spellmann; M. Riedel; R.L. Musil; A. Douhet; S. Dehning; P. Zill; N. Müller; H.J. Möller; B. Bondy (S378-S379).

P.3.a.035 Psychoeducation and compliance in the treatment of the patients with schizophrenia by D. Degmecic; I. Požgain; M. Grgic; P. Filakovic (S383).

P.3.a.038 Insight and depressive symptoms in first episode psychosis by S. Aspiazu; J. Ruiz; A. Aldama; K. Haidar; M. Alonso; I. Ruiz; J.A. Micó; A. González-Pinto (S385).

P.3.a.032 Cognitive efficacy of quetiapine and olanzapine in early onset first episode psychosis by O. Robles; A. Zabala; M.J. Parellada; A. Ruiz; M.D. Moreno; M.T. Burdalo; C. Arango (S381-S382).

P.3.a.028 Cognitive correlates of proton magnetic resonance spectroscopy measures in patients with first-episode schizophrenia by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; W. Dzienis; A. Czernikiewicz; J. Walecki (S379).

P.3.a.029 First psychotic episodes:predictive factors in a 3-years follow up study by M. Arrasate; C. Valcarcel; B. Farnandez de Corres; F. Ramirez; J.L. Figuerido; A. González-Pinto; M. Garcia (S380).

P.3.a.031 Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people by C. Henquet; L. Krabbendam; J. Spauwen; C. Kaplan; R. Lieb; H.U. Wittchen; J. Van Os (S381).

P.3.c.009 Valproate and psychotropic drug interactions by J. Glen; J. Fleming; M. Herman; M. Chetty (S401).

P.3.c.045 Treatment of agitation caused by severe mental illness: data from the South London and Maudsley intensive care units trial evaluation (SLAMICUTE) study by V. Mantua; M.J. Travis; Z. Atakan; M.B. Isaac; M.T. Isaac; S. Smith; D. Gilbert; J. Komeh; A. Shaw; C. Sweeney; R.W. Kerwin (S420-S421).

P.3.c.044 Plasma antioxidant status in first psychotic episode patients before and after antipsychotic treatment by M.O. Rojas-Corrales; F. Mosquera; A. Aldama; C. González; A. González-Pinto; J.A. Micó (S420).

P.3.c.048 Antipsychotic safety: should we believe in guinea-pigs by D. Barrocas; M. Abreu; L. Figueira (S422-S423).

P.3.c.043 Association of leptin gene polymorphism with antipsychotic drug-induced weight gain by S.H. Ryu; W.S. Jang; E.Y. Cho; S.K. Kim; D.S. Lee; K.S. Hong (S419-S420).

P.3.c.042 Zotepine-induced mania: two cases report by C.C. Liang; J.Y. Chen; T.T. Chen; Y.M. Bai (S419).

P.3.c.037 Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia by N. Mossaheb; J. Sacher; G. Wiesegger; N. Klein; C.J. Spindelegger; S. Asenbaum; R. Dudczak; S. Kasper (S416).

P.3.c.040 The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder: results for 16-week clinical study by J.G. Kim; D.H. Cho; S.J. Lee; J.K. Lee; K.S. Wang; Y.I. Seo; S.J. Choi; M.J. Joo; H.D. Kim; K.H. Lee; Y.J. Kwon; K.R. Han (S417-S418).

P.3.c.041 −759 C/T polymorphism of the 5-HT2C receptor gene and antipsychotic drug-induced weight gain by S.H. Ryu; W.S. Jang; E.Y. Cho; S.K. Kim; D.S. Lee; T.S. Park; S.H. Oh; K.S. Hong (S418-S419).

P.3.c.049 Aggression and psychopathology in an acute psychiatric sample:clinical and therapeutic considerations by A. Colasanti; M. Rossattini; D. Moliterno; A. Natoli; M.C. Mauri (S423).

P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study by C. Arango; J. Bobes; P. Aranda; R. Carmena; M. Garcia-Garcia; J. Rejas (S423-S424).

P.3.c.058 Emotion recognition deficit in first-episode schizophrenic patients and atypical antipsychotics by G.P.A. Amminger; S.W. Werneck-Rohrer; H.N.A. Aschauer; J.E. Edwards; M.S. Schloegelhofer (S427-S428).

P.3.c.051 Is risperidone an atypical antipsychotic? by D. Marinkovic; S. Totic; M. Marjanovic (S424).

P.3.c.035 SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics by R.L. Musil; I. Spellmann; M. Riedel; A. Douhet; S. Dehning; K. Maino; P. Zill; N. Müller; H.J. Möller; B. Bondy (S415).

P.3.c.018 Genetic predictors of cognitive function and response to treatment in schizophrenia by A. Ertugrul; A.E. Anil Yagcioglu; N.D. Woodward; K. Jayathilake; H.Y. Meltzer (S406).

P.3.c.017 Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia by J.C. Shim; D.L. Kelly; D.U. Jung; Y.S. Seo; Y.H. Kim; R.R. Conley (S405-S406).

P.3.c.015 Pre-attentive processes and attention: effect of risperidone for 6 weeks in untreated patients with schizophrenia and correlation with disorganization by I. Amado; C. Daban; M.F. Poirier; M.C. Bourdel; D. Willard; P. Bouhours; H. Lôo; M.O. Krebs (S404-S405).

P.3.c.012 Discontinuation rate of antipsychotic drugs in the treatment of first treated schizophrenia by J.C. Shim; B.M. Choe; Y.M. Jae; J.G. Kim; H.C. Kim; S.G. Kim (S402-S403).

P.3.c.013 The prevalence of bone mineral density loss in the Korean patients with chronic schizophrenia by J.C. Shim; D.U. Jung; S.H. Yoon; J.G. Kim; Y.M. Jae; B.M. Choe; H.C. Kim; S.G. Kim (S403).

P.3.c.014 Side effects of atypical antipsychotics - prediction factor for compliance by A. Baloescu; D. Vasile; M.D. Gheorghe; G. Grigorescu (S404).

P.3.c.023 Comorbidity associated with the use of antipsychotic drugs: a population study in the primary care setting by M. Blanca Tamayo; A. Sicras Mainar; J. Rejas Gutierrez; R. Navarro Artieda; J. Serrat Tarres; M.A. Ruiz Diaz; N. Muro Perea (S409).

P.3.c.032 Risperidone long acting im formulation in high risk of noncompliance bipolar patients by D. Vasile; O. Vasiliu; D. Ojog; M.D. Gheorghe (S413-S414).

P.3.c.033 FDG-PET and MRI imaging of the effects of sertindole in the striatum in schizophrenia by M.S. Buchsbaum; A. Gupta; M.M. Haznedar; E. Hazlett; K.W. Chu; K. Goldstein; C. Goodman; R. Newmark; Y. Torosjan; N. Bark; A. Wolkin (S414).

P.3.c.034 Comparing the use and outcomes of antipsychotics in the real world by A.M. Taylor; P. Shajahan; R. Carleton (S414-S415).

P.3.c.028 Effectiveness of aripiprazole versus standard of care treatment in patients with schizophrenia: the Schizophrenia Trial of Aripiprazole (STAR) study by R. Kerwin; G. L'Italien; L. Hanssens; R.N. Marcus; R. McQuade; W.H. Carson; J.N. Beuzen (S411-S412).

P.3.c.024 Negative and cognitive symptomatology improvement during aripiprazole treatment in chronic schizophrenia by M.D. Gheorghe; V.A. Voicu; D. Vasile; O. Vasiliu; G. Grigorescu (S409-S410).

P.3.c.026 Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up by C.C. Lin; J.Y. Chen; Y.M. Bai; T.T. Chen; Y.C. Wang; Y.J. Liou; W.K. Lin (S410-S411).

P.3.c.027 Pattern of neuroleptic drug use in acute schizophrenia by D. Gruenler; C. Bunk; M. Specka; M. Gastpar; E. Davids (S411).

P.6.a.002 Lamotrigine in treatment of delirium tremens by G. Djokic; N. Zivkovic; D. Lazic; S. Jakulic; A. Dostanic (S490).

P.8.b.006 Involvement of α2-adrenoceptors in the local peripheral anti-hyperalgesic effect of carbamazepine by M. Tomic; S. Vuckovic; R. Stepanovic-Petrovic; N. Ugresic; M. Prostran; B. Boskovic (S566-S567).

P.8.b.007 Gaboxadol does not generalise to other sleep-enhancing agents in drug discrimination in rats by L.M. McDonald; W.E. Sheppard; D. Tattersall; P.H. Hutson; S. Staveley; B. Sohal (S567).

P.8.b.003 Computed studies on a 3-D model of human head comparing effectiveness and safety of ECT and TMS by T. Zyss; B. Sawicki; A. Krawczyk; J. Starzynski; R. Szmurlo; S. Wincenciak; M. Siwek (S565).

P.8.a.055 Attitudes toward psychiatry among medical students - factors associated to selection of psychiatry as a career by A. Herran; M. Carrera; A. Andres; M. Jalon; J.L. Vázquez-Barquero; J. Llorca (S563).

P.8.a.054 Zolpidem compared to flurazepam and placebo in alcoholics by M.J.K. Jakovcevska Kujundziska; V.L. Lazarova; N.C. Cadikovska; V.F. Filovska (S562).

P.8.b.001 Prevalence rates of major mental disorders in mental health related facilities in Korea by S.J. Cho; J.I. Park; J.N. Bae; B.J. Hahm; J.Y. Lee; M.J. Cho (S563-S564).

P.8.b.010 Study of Cloninger's dimension of personality in patients with mood disorders by M. Abd El Meguid; M. Kamel; A.N. Omar; Y. Abd El Razek (S568).

P.8.b.011 Familial risk and prodromal features of psychosis in adolescents aged 15-16 years in the northern Finland 1986 birth cohort by P.H. Mäki; J. Miettunen; A. Taanila; I. Moilanen; M. Joukamaa; E. Lauronen; P.B. Jones; J.M. Veijola (S569).

P.8.b.012 Hepatitis C, interferon and depression by G.J.O. Granada; S.R.J. Sanchez; A.V.T. Artaza; M.S.P. Morales; G.S.C. Galan (S569-S570).

P.8.b.013 Bipolar disorder alters peripheral benzodiazepine receptors by S. Baroni; I. Masala; G. Giannaccini; M. Catena; L. Bevilacqua; B. Dell'Osso; D. Marazziti (S570).

P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder by G.M. Gharabawi; C.M. Canuso; G.J. Pandina; C.A. Bossie; M. Kujawa; C. Kosik-Gonzalez; I. Turkoz (S562).

P.8.a.052 Suicide attempters, stress and peripheral benzodiazepine receptors by M. Catena; S. Baroni; I. Masala; B. Dell'Osso; A. Baldini; G. Giannaccini; D. Marazziti (S561).

P.8.a.035 Lorazepam-induced reduction in activity mirrors decrements in cognitive and psychomotor performance by J. Dawson; J. Boyle; N. Stanley; S. Johnsen; I. Hindmarch; D.J. Skene (S552-S553).

P.8.a.037 The Verona brain imaging study in schizophrenia: an integrated project with epidemiology and social psychiatry by N. Dusi; M. Tansella; A. Versace; N. Andreone; G. Rambaldelli; C. Perlini; C. Barbui; M. Nosè; D. Cristofalo; A. Gasparini; R. Cerini; P. Brambilla (S553-S554).

P.8.a.038 Sedative/hypnotic use and trends among United States elderly by D.A. Sclar; T.L. Skaer; L.M. Robison (S554).

P.8.a.033 Case-report of right unilateral anterior capsulotomy for obsessive-compulsive disorder by G. Degraeve; K. Audenaert; D. Van Den Abbeele; C. Van Heeringen; J. Caemaert; D. Van Roost (S551-S552).

P.8.a.032 Effects on sleep of caffeine and its combination with trazodone or zolpidem in healthy volunteers by L. Paterson; M. Ivarsson; P. Hutson; D.J. Nutt; S.J. Wilson (S551).

P.8.a.028 The role of gender in mixed mania: testing different definitions for mixed manic states by A. Aldama; F. Mosquera; C. González; S. Ron; J.R. Peciña; S. Aspiazu; A. González-Pinto (S548-S549).

P.8.a.026 Double blind trial of amantadine and haloperidol for treatment of delirium by Y.R. Kim; H.Y. Jung; I.S.Y. Lee; Y.J. Kwon; S.H. Cho; J.H. Hong (S548).

P.8.a.029 Obesity and eating disorders: analogies and differences by A. Goracci; G. Capano; I. Soreca; E. Cigna; C. Ciuoli; A. Di Muro; P. Castrogiovanni; F. Pacini (S549).

P.8.a.030 Validation of a translational model of insomnia in rats and human volunteers by L. Paterson; M. Ivarsson; P. Hutson; D.J. Nutt; S.J. Wilson (S550).

P.8.a.031 Anxiety, family support and alexithymia in patients with bronchial asthma by A. Tselebis; A. Karkanias; D. Bratis; K. Giotakis; G. Moussas; I. Ilias; K. Vassila-Demi (S550).

P.8.a.039 Driving ability in adults with attention-deficit hyperactivity disorder significantly improves when treated with methylphenidate by J.C. Verster; E.M. Bekker; M. De Roos; A. Minova; E.J.E. Eijken; U.S. Kooij; J.K. Buitelaar; J.L. Kenemans; M.N. Verbaten; B. Olivier; E.R. Volkerts (S554-S555).

P.8.a.047 Searching susceptibility loci for maniacal and depressive polarities in bipolar disorders: a sib pairs study on chromosome 12 by C. Lorenzi; A. Pirovano; D. Dotoli; F. Bongiorno; E. Marino; M. Catalano; E. Smeraldi (S559).

P.8.a.049 Assessment of cortical lobe perfusion in schizophrenia: a magnetic resonance imaging study by M. Bellani; M. Tansella; C. Perlini; R. Cerini; G. Rambaldelli; M. Balestrieri; P. Brambilla (S560).

P.8.a.050 Gender differences in mood spectrum: clinical aspects by M. Carlini; L. Bevilacqua; P. Rucci; A. Baldini; C. Carmassi; F. Golia; L. Dell'Osso (S560-S561).

P.8.a.051 Attachment styles in patients with mood and anxiety disorders by A. Del Debbio; F. Mungai; L. Vivarelli; B. Dell'Osso; C. Carmassi; M. Carlini; D. Marazziti (S561).

P.8.a.046 Are zolpidem-induced amnesia and somnambulism rare incidences? by C.C. Chen; P. Yang; W.L. Chung; W.Y. Chour (S558-S559).

P.8.a.041 The correlation of dream recall and clinical variables in narcoleptics by S.P. Lee; J.H. Jeong; S.H. Hong; J.H. Han (S555-S556).

P.8.a.042 Persistent executive deficit in euthymic bipolar outpatients: a 2-year follow-up study by M. Mur; M.J. Portella; A. Martinez-Aran; J. Pifarre; E. Vieta (S556-S557).

P.8.a.043 Suggestion for safer prescription from the investigation on psychotropic drugs of suicide attempters by D. Kato; C. Kawanishi; T. Yamada; H. Hasegawa; R. Sato; I. Kishida; T. Furuno; Y. Hirayasu (S557).

P.8.a.044 Neuropsychological functioning in stabilised patients after a first psychotic episode by A. Jimenez; C. Gonzalez Gomez; A. Palomino; M.G. Dominguez; P. Vega; R. Gonzalez Oliveros; A. González-Pinto (S557-S558).

C.16.04 New treatment options for OCD by N. Fineberg (S586).

Keyword Index (S611-S617).

C.06.04 Pharmacological treatment of adult ADHD by J.K. Buitelaar (S576-S577).

C.05.02 Antidepressants in pain by P. Delgado (S575).

C.12.02 Is depression neurodegenerative? by T.E. Schläpfer (S581).

C.12.01 Current controversies in depression treatment: a hot topics panel by J.E. Alpert; M. Detke; Y. Lecrubier; T.E. Schläpfer (S581).

C.12.03 Taking remission to the next level by J.E. Alpert (S581-S582).

C.11.03 Why do medications fail? by S. Keith (S580-S581).

P.8.a.025 Testosterone levels in young male patients with affective disorder and schizophrenia by A. Rajewska-Rager; J. Rajewska; K. Kaminska; J. Rybakowski (S547-S548).

P.6.d.004 Brain imaging study on the effects of delta-9 THC on orientation and motor coordination in regular users of marijuana by A. Weinstein; O. Brickner; H. Lerman; M. Greemland; M. Bloch; R. Mechoulam; H. Lester; R. Bar Hamburger; R. Chisin; E. Even-Sapir (S509).

P.6.d.005 mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behaviour in rats by O. Dravolina; E.S. Zakharova; E.V. Shekunova; E.E. Zvartau; W. Danysz; A.Y. Bespalov (S509-S510).

P.6.c.009 Benzodiazepine dependence disorder in a detoxification unit-aprospective study from 1993 to 2003 by N. Espluga Frigola; M.A. Malagon Amor; M.F. Fonseca Casals; C. Garnier Lacueva; G. Mateu Codina; M. Torrens Melich (S505).

P.6.c.008 One year retention rates and outcomes methadone and buprenorphine maintenance treatments: a nationwide prospective-longitudinal study of 2694 patients by H.U. Wittchen; S.M. Apelt; M. Soyka; M. Gastpar; M. Backmund; J. Goelz; M. Kraus; F. Tretter; M. Schaefer; J. Siegert; A. Guenther; J. Rehm; G. Buehringer (S504-S505).

P.6.c.010 The effects of cannabinoids in man: a systematic review of neuroimaging studies by A.B. Fagundo; R. Martín-Santos; J.A. Crippa; M. Seal; Z. Atakan; P. McGuire (S505-S506).

P.6.c.011 Pathological gambling:treatment correlates by A.V. Ravindran; J. Telner; R. Bhatla; C. Cameron; E. Horn; D. Horner; L. Cebulski; S. Davies (S506).

P.6.d.017 Up-regulation of dopamine D3 receptor expression following continuous infusion of nicotine by M. Mugnaini; C. Corti; S. Mion; C.A. Heidbreder; M. Tessari (S516).

P.6.d.018 New group of positive modulators of AMPA-receptors with cognition enhancing properties by V.V. Grigoriev; M. Lavrov; V.A. Palyulin; N.S. Zefirov; B.K. Besnosko; S.O. Bachurin (S516-S517).

P.6.d.019 Differential involvement of corticosterone and ghrelin on extinction of cocaine self administration and on cocaine-associated cue-induced reinstatement in rats by M. Tessari; A. Catalano; M. Pellitteri; F. Marini; C. Righetti; C. Di Francesco; P.A. Gerrard; C.A. Heidbreder; S. Melotto (S517).

P.6.d.015 MDMA self-administration is abolished in serotonin transporter knockout mice by J.M. Trigo Díaz; T. Renoir; L. Lanfumey; M. Hamon; P. Robledo; R. Maldonado (S514-S515).

P.6.d.014 Intrahippocampal inhibition of protein kinase A attenuates morphine-induced conditioned place preference by M. Sharifzadeh; P. Tahsili-Fahadan; A. Haghighat; A.R. Zamanian (S514).

P.6.c.007 Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability by H.U. Wittchen; P. Zimmermann; F. Waszak; A. Nocon; M. Hoefler; R. Lieb (S504).

P.6.a.012 Alcohol detoxification improves depressive symptomatology by J.A. Liappas; E.O. Tzavellas; T.J. Paparrigopoulos; C.R. Soldatos (S495).

P.6.a.013 Sleep problems in alcohol dependence by T.J. Paparrigopoulos; E.O. Tzavellas; J.A. Liappas; C.R. Soldatos (S495-S496).

P.6.a.015 Cognitive topography imbalance in alcoholism and psychiatric comorbidity by P. Papart; F. Liota; F. Bartholomé; M. Ansseau (S496).

P.6.a.005 The role of dopamine 2 receptor gene and personality characteristics in alcohol dependence in Turkish population by A. Kitis; Y. Akvardar; C. Eresen; S. Kizildag; U. Akpulat; S. Yildirimcan; K. Alptekin; B.B. Akdede; H. Arkar (S491).

P.6.a.003 Oxcarbazepine in alcohol relapse prevention - a randomized open trial by B. Croissant; A. Diehl; O. Klein; H. Nakovics; A. Heinz; K. Mann (S491).

P.6.a.006 Temperament differences between early and late onset male alcoholic patients by S.W. Lim; K.S. Oh; Y.C. Shin; J.W. Paik; H.J. Lee; J.G. Kim; S.J. Yang; H.T. Kim; S.B. Paik; Y.H. Jin (S492).

P.6.a.007 Risks and pattern of alcohol withdrawal delirium by B. Maneeton; N. Burapakajornpong; M. Srisurapanont (S492-S493).

P.6.a.008 Emotional awareness deficits in patients with alcohol dependence by J.J. Lee; U.S. Chung; Y.T. Kim; D.H. Kwon (S493).

P.6.c.002 Attention deficits in schizophrenic patients with comorbid substance abuse by K. Krysta; A. Klasik; I. Krupka-Matuszczyk; M. Sygut; L. Hubicki (S501).

P.6.c.001 Benzodiazepines misuse in outpatients treated by internists by M. Srisurapanont; S. Suttajit; P. Lerttrakarnnon (S500-S501).

P.6.c.004 Are benzodiazepine expenses judiciously invested? by J. Irurita; M. Irurita; C. Deniz; M.T. Martinez Saavedra; C. Culebras; M.S. Rodriguez; B. Ania; J.M. Saavedra; R. Chirino; F. Sanchez (S502-S503).

P.6.c.005 Meta-analyses of opiate maintenance therapies by M. Ansseau; J. Reggers; L. Somers; F. Richy; P. Van Deun; B. Sabbe (S503).

P.6.b.008 Modulation of gabaergic transmission in alcoholic subjects and sons of alcoholics by T.F. Dielentheis; M. Schreckenberger; C. Landvogt; K. Hobusch; J. Hirsch; K. Mann; P. Bartenstein; G. Gründer (S500).

P.6.b.007 Is there an association between nicotine dependence and compulsive alcohol craving? by T. Hillemacher; K. Bayerlein; J. Wilhelm; H. Frieling; S. Bleich (S500).

P.6.b.005 Effects of olanzapine on ethanol withdrawal syndrome in rats by N. Unsalan; H. Kayir; E. Saglam; I.T. Uzbay (S499).

P.6.b.006 The role of epigenetic HERP dysregulation in patients with alcohol dependence by S. Bleich; B. Lenz; D. Bönsch; H. Frieling (S499-S500).

P.6.d.022 Behavioural responses induced by nicotine in delta-opioid receptor knockout mice by F. Berrendero; L. Galeote; A. Bura; B.L. Kieffer; R. Maldonado (S518-S519).

P.8.a.008 The utility of structural neuroimaging in the psychiatric inpatients by M.P.G. Pérez; Y.P.R. Prado; M.P.F. Páramo (S538-S539).

P.8.a.009 Hyponatremia during psychopharmacological treatment - results of a drug surveillance program by M. Letmaier; A. Konstantinidis; C. Egger; R. Grohmann; S. Kasper (S539).

P.8.a.010 Effects of galantamine on serum vitamin B12 and folic acid levels in patients with chronic fatigue immune dysfunction syndrome by A. Asdemir; S. Ozsoy; H.B. Izgi; M. Kula; M. Deveci; B. Yildiz; T. Turan; E. Esel; M. Basturk; M. Kirnap; S. Sofuoglu (S539-S540).

P.8.a.005 Familial heritability of increased homocysteine in schizophrenia by V. Geller; J. Levine; Y. Bersudsky; R.H. Belmaker (S537).

P.8.a.004 Nocturnal eating episodes after taking zolpidem: are they sleep problems or eating problems? by J.M. Kim; Y.C. Kim; H.B. Shin; W.J. Lim; K.W. Yun; K.W. Paik (S536-S537).

P.7.e.002 Concentrations and glycosylations profile of acute phase proteins in anorexia nervosa by R. Komorowska-Pietrzykowska; A. Rajewski; M. Sobieska; K. Wiktorowicz (S534-S535).

P.7.e.001 Serum concentrations of interleukin 4 and interleukin 10 in patients suffering from anorexia nervosa by R. Komorowska-Pietrzykowska; A. Rajewski; M. Sobieska; K. Wiktorowicz (S534).

P.8.a.011 Effects of galantamine on serum progesterone and DHEAS levels in female patients with chronic fatigue immune dysfunction syndrome by H.B. Izgi; A. Asdemir; F. Tanriverdi; S. Ozsoy; E. Esel; T. Turan; M. Basturk; B. Yildiz; Z. Candan; F. Kelestimur; S. Sofuoglu (S540).

P.8.a.012 Subtle cognitive impairments in siblings of male adolescents with non-psychotic psychiatric disorders by M. Weiser; A. Reichenberg; E. Kravitz; G. Lubin; M. Shmushkevitz; S. Noy; M. Davidson (S541).

P.8.a.020 Dopaminergic, noradrenergic, adrenal and thyroid abnormalities in schizoaffective disorder by F. Duval; M.C. Mokrani; J.A. Monreal Ortiz; C. Champeval; N. Chokmani; J.P. Macher (S545).

P.8.a.019 Seasonally of cortisol secretion by A.L. Morera; P. Abreu; M. Henry; A. Garcia-Hernandez; F. Guillen-Pino; R. Gracia (S544-S545).

P.8.a.022 Analysis of the hospitalized frustrated suicides, classified according to the violence of the method used by C. Castro Dono; F. Iglesias Gil de Bernabé; J. García Fernández; M. Filgueira Bouza; E. Fontela Vivanco; S. Segade Rodríguez; S. González Bardanca; J. Alberdi Sudupe; L. Ferrer i Balsebre; M. Amboage Paz (S546).

P.8.a.023 Lifetime comorbidity in bipolar disorder: bipolar subtype and gender differences by B. Grabski; D. Dudek; W. Datka; G. Maczka; A. Zieba (S546-S547).

P.8.a.017 A flexible dose open label trial evaluating the efficacy and safety of quetiapine as adjunctive pharmacotherapy for the treatment of generalized anxiety disorder (GAD) by M.A. Katzman; M. Vermani; L. Jacobs; M. Marcus; S. Lessard; W. Galarraga; B.Y. Kong; L. Struzik; A. Gendron (S543).

P.8.a.013 Personality disorders in a sample of schizophrenic patients by M. Henry; A.L. Morera; A. Garcia; L. Fernandez; I. Fernandez; R. Gracia (S541).

P.8.a.014 Long-term evolution follow-up of patients treated with electroconvulsive therapy by M.T.A. Tajes; S.M.F. Martínez; M.P.F. Páramo (S541-S542).

P.8.a.015 EEC-sleep profiles, hypothalamic-pituitary-adrenocortical (HPA) activity, and association with psychological/behavioural variables in pre-schoolers by M. Hatzinger; S. Brand; S. Perren; S. Stadelmann; A. von Wyl; K. von Klitzing; E. Holsboer-Trachsler (S542).

P.8.a.016 Impact of cerebrovascular accident on medical service resource utilization in a regional hospital by A. Sicras Mainar; R. Navarro Artieda; M. Blanca Tamayo; J.R. Llopart Lopez; J. Serrat Tarres; J. Rejas Gutierrez (S542-S543).

P.7.d.003 The validity of the quality of life enjoyment and satisfaction questionnaire in adults with ADHD by E. Mick; J. Biederman; T. Spencer; S.V. Faraone; H. Zhang (S533).

P.7.a.001 Obsessive-Compulsive syndrome in adolescent schizophrenia by M. Hrdlicka; P. Kollarova; I. Dudova (S523).

P.6.f.003 Effects of neonatal serotonin depletion on reinforcing and rewarding properties of cocaine in rats by R. Stefanski; P. Krzascik; P. Kolomanska; P. Rock; E. Wyszogrodzka; W. Kostowski (S522-S523).

P.7.a.003 Divalproex sodium for the treatment of irritability in autism by E. Anagnostou; W. Chaplin; J. Rusoff; L. Soorya; E. Hollander (S524).

P.6.f.002 Behavioural sensitization to nicotine in drug discrimination procedure by H. Kayir; U. Yazgan; O. Yavuz; B. Acikmese; I.T. Uzbay (S522).

P.6.d.024 C385A FAAH SNP is related to substance use disorder but not to schizophrenia in a Spanish sample by I. Martínez-Gras; G. Ponce; R. Rodriguez-Jimenez; G. Rubio (S519-S520).

P.6.e.001 State and trait anxiety, smoking and gender by D. Zullino; E. Fresard; Y. Khazaal; A. Chatton; J.G. Bavarel; Y.A. Kaufmann; D. Benguettat; R. Khan; R. Annoni Manghi (S520).

P.6.e.002 Efficacy of sertraline in the treatment of alcohol dependence by V.L. Lazarova; M.J.K. Jakovcevska Kujundziska; V.F. Filovska; R.K. Krstevska (S520-S521).

P.7.b.001 Prefrontal N-acetyl-aspartate and cognition in adolescents with first-episode psychosis by A. Zabala; J. Sánchez; O. Robles; D. Moreno; M.T. Burdalo; M.J. Parellada; P. Laita; M. Desco; C. Arango (S525-S526).

P.7.b.002 Association of DAO and DAOA genes with autism spectrum disorders in Korean boys by J.W.J. Jeon; S.H.C. Chung; J.P.H. Hong; H.I.Y. Yoo (S526).

P.7.d.001 Functional MRI of response inhibition in autism by E. Anagnostou; J. Fan; E. Hollander (S531-S532).

P.7.c.006 Antipsychotic drugs in children and adolescents: QTc interval elongation by P. Laita; C. Franco; C. Llorente; A. Cifuentes; A. Ulloa; D. Fraguas; C. Arango (S529-S530).

P.7.c.005 Pharmacokinetics, detection, likeability and dislikeability of two formulations of long-acting oral methylphenidate by T.J. Spencer; J. Biederman; P. Ciccone; B. Madras; D.A. Parasrampuria; A.J. Fischman; E. Mick; J. Martin; T. McDonnel (S529).

P.3.a.013 Untreated patients with schizophrenia have a failure of inhibitory control systems during saccadic tasks by M.O. Krebs; M.C. Bourdel; H. Picard; S. Morel; S. Gray; P. Bouhours; H. Lôo; I. Amado (S371).

P.1.a.015 Strain differences in susceptibility to unpredictable chronic mild stress as assessed by hippocampal gene expression profiling by J.L. Paya-Cano; F. Sluyter; Y.S. Mineur; C. Fernandes; W.E. Crusio; L.C. Schalkwyk (S216-S217).

P.1.a.016 Genetic and biological markers of families of patients with schizophrenia by L.A. Ryadovaya; E.V. Gutkevich; L.P. Pitina; L.A. Gorbacevich (S217).

P.1.a.011 Nature and nurture predispose to violent behaviour: on serotonergic genes and adverse childhood environment by A. Reif; M. Schneider; C.M. Freitag; P. Retz-Junginger; M. Rösler; C.P. Jacob; K.P. Lesch; W. Retz (S214).

P.1.a.007 Retinoid function related genes do not cause psychosis in a large inbred family by S. Ozer; B. Akýn; A. Uluşahin; N. Akarsu (S211-S212).

P.1.a.010 The C270T and Val66Met polymorphisms of brain-derived neurotrophic factor in schizophrenia by A. Juhász; Á. Rimanóczy; S. Kéri; C. Cimmer; G. Szekeres; I. Szendi; Z. Janka (S213-S214).

P.1.b.002 Anterior cingulate volumes in schizophrenia: a systematic research review and a meta-analysis of MRI studies by M. Baiano; A. David; A. Versace; R. Churchill; M. Balestrieri; P. Brambilla (S218).

P.1.b.003 Non-invasive measurement of vagus activity in the brainstem - a methodological progress towards earlier diagnosis of dementias? by A.J. Fallgatter; T. Polak; F. Metzger; M.M. Plichta; T. Ringel; A.C. Ehlis (S218-S219).

P.1.b.012 Relationship between kynurenines and S100b in CSF of schizophrenic patients by M.J. Schwarz; M. Riedel; S. Holdenrieder; S. Erning; M. Tischinger; N. Müller (S223).

P.1.b.010 Low concentrations of plasma brain-derived neurotrophic factor in patients with panic disorder by J.C. Yang; Y.K. Kim; M.S. Lee; J.S. Yoon; S.J. Eun; H.Z. Cao (S222).

P.1.b.009 Neural stem cell proliferation is significantly reduced in schizophrenia, but not in affective psychoses by A. Reif; S. Fritzen; M. Finger; A. Strobel; A. Schmitt; K.P. Lesch (S221-S222).

P.1.b.004 Cortisol in stress response dampening in subjects at risk for alcoholism by B. Croissant; R. Olbrich; R. Demmel; F. Rist (S219).

P.1.b.006 Characterization of Gpr101 expression and G protein-coupling selectivity by M.H. Pausch; L. Zhang; S. Nawoschik; E. Tseng; K. Sreekumar; A. Kramer; Q. Shan; N. Taylor; J. Paulsen; B. Bates (S220).

P.1.b.007 Heart rate variability in patients with anxiety disorders by J. Dragasek; M. Drimalova; P. Durdik; M. Migra; G. Holla (S220-S221).

P.1.a.004 The association of promotor polymorphism in synapsin III gene with schizophrenia by L.C.H. Lee; P.J.H. Park; K.C.Y. Kim; H.O.S. Han; J.Y.H. Joo (S210).

S.26.04 Do genes predict cognitive dysfunction in schizophrenia? by N. Andreasen; B.C. Ho; T. Wassink (S202).

S.27.02 Social isolation and brain function by C. Marsden; M. Bianchi; M.C. Pardon; V. Porkess; K.C.F. Fone (S202-S203).

S.28.01 Discovery and function of TPH2 by G. Vodjdani; C. Fligny; J. Mallet; F. Côté (S203).

S.26.01 Neurotransmitter genes in causation and treatment response by P. Gorwood; N. Hamdani; C. Dubertret; C. Boni (S201-S202).

S.25.01 Epidemiology of smoking and co-morbid pychiatric disorders by P. Cuijpers; R. Van der Meer; M. Ten Have; R. De Graaf (S200).

S.28.02 Influence of variants of TPH2 on the regulation of the central serotonin system by M.G. Caron; X. Zhang; J.M. Beaulieu; R.R. Gainetdinov; T. Sotnikova (S203-S204).

E.06.02 Gender differences: focus on anxiety and depression by D. Marazziti; L. Bevilacqua; M. Catena (S207).

E.06.01 Gender differences: focus on addiction by G. Fischer; N. Ebner; B. Winklbaur; K. Thau (S206-S207).

P.1.a.001 Serotonin 5-HT1B gene polymorphism (C129T) in homicidal schizophrenics by S.K. Wang; I.H. Jeong; I.S. Chee; Y.O. Shin; S.W. Lee (S209).

P.1.a.002 Protective effect of haplotype of dysbindin gene (DTNBP1) on chromosome 6p22.3 to major depressive disorder by J.J. Kim; C.U. Pae; T.S. Kim; C.U. Lee; S.J. Lee; C. Lee; T.Y. Jun; I.H. Paik (S209-S210).

P.1.a.003 The serotonin transporter gene: association with different psychiatric disorders by D. Gaysina; A. Zainullina; E. Jurjev; G. Faskhutdinova; T. Noskova; E. Khusnutdinova (S210).

E.04.02 Treatment of adult ADHD by E. Taylor (S206).

S.28.04 TPH expression in human brain and its importance for psychiatric disorders by M. Ackenheil; B. Bondy; A. Buttner; P. Zill (S204).

E.04.01 Diagnosis and assessmentof adult ADHD by J.K. Buitelaar (S205-S206).

P.1.c.041 Fluorescence in vitro studies of human adenosine A2A and serotonin 5HT1A receptors homodimerization by S. Lukasiewicz; E. Blasiak; A. Faron-Gorecka; Z. Wasylewski; M. Dziedzicka-Wasylewska (S245-S246).

P.1.c.043 The effects of risperidone, olanzapine and haloperidol on enzyme activities in kidney tissue of rats by M. Gulaboglu; Z. Halici; N. Aydin; E. Cadirci; M. Gul; H. Suleyman; E. Oral (S246-S247).

P.1.c.037 Mitochondria as the memantine target by E.P. Shevtsova; L.G. Dubova; E.G. Kireeva; S.O. Bachurin (S243-S244).

P.1.c.034 Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food by C. Souppart; A. Gardin; G. Greig; S. Balez; Y. Batard; A. Krebs-Brown; S. Appel-Dingemanse (S242).

P.1.c.044 Efficacy and mechanism of antidyskinetic activity of sarizotan by G.D. Bartoszyk; M. Gerlach; M. Van den Buuse; P. Riederer (S247).

P.1.c.045 The effects of risperidone, olanzapine and haloperidol on enzyme activities in erythrocytes and plasma of rats by Z. Halici; F. Ozabacigil; N. Aydin; M. Gulaboglu; M. Gul; H. Suleyman (S247-S248).

P.1.d.004 Effects of a selective and brain penetrating 5-HT6 receptor antagonist in animal models of depression and anxiety by A. Wesolowska; A. Nikiforuk; K. Stachowicz; E. Chojnacka-Wojcik (S251-S252).

P.1.d.006 Behavioral phenotyping of sodium-myo-inositol cotransporter knockout mice with reduced brain inositol by Y. Bersudsky; A. Shaldubina; R. Johanson; R. Buccafusca; G. Agam; R.H. Belmaker; G. Berry (S252-S253).

P.1.d.002 Aggressive and hyperactive behavioural characteristics is increased in maternal social separated rat by H.R. Kwak; J.I. Park; H.J. Ko; S.J. Kim; Y.S. Choi; H.J. Lee (S250-S251).

P.1.c.047 A double-blind, placebo-controlled investigation of the anxiolytic effects of XBD173 (AC-5216) and alprazolam using a CCK-4-induced panic challenge by R. Rupprecht; D. Eser; C. Schuele; K. Kucher; M. Merz; A. Krebs-Brown; A. Floesser; X. Lataste; I. Bruenig-Traebert; R. Zaninelli (S248-S249).

P.1.c.031 Effect of acute and chronic light/dark cycle alteration on seizure threshold in mice: modulation by melatonin by N. Yahyavi-Firouz-Abadi; P. Tahsili-Fahadan; K. Riazi; A.R. Dehpour (S240).

P.1.c.030 Antidepressant treatment reduces fos-like immunoreactivity in different regions of periaqueductal gray matter by R.M.W. Oliveira; C. Lino-de-Oliveira; A.P. Carobrez; T.C.M. De Lima; E.A. Del Bel; F.S. Guimãraes (S239-S240).

P.1.c.013 NMDA receptors of the central amygdala are involved in morphine-induced conditioned place preference by F. Golhasani-Keshtan; A. Rezayof; M.R. Zarrindast; A. Haeri Rohani; F. Nazari-serenjeh; L. Delphi (S230).

P.1.c.015 The role of voltage dependent sodium channels on the antidepressant-like effect of lamotrigine by F.T. Codagnone; F.T. Consoni; A.L.S. Rodrigues; M.A.B. Vital; R. Andreatini (S231-S232).

P.1.c.009 Ethanol state-dependent learning: involvement of dopamine D2 receptors of dorsal hippocampus by A. Rezayof; T. Motevasseli; Y. Rassouli; M.R. Zarrindast; R. Amini (S228).

P.1.c.024 Effects of haloperidol on intracellular calcium ion change in hamster insulinoma cells by M.H. Kim; J.H. Shin; K.C. Park; G.S. Park; I.D. Gong; T.H. Kim (S236-S237).

P.1.c.020 Regulation of cytochrome P-450 activity by the brain dopaminergic system by J. Wójcikowski; K. Gołembiowska; W.A. Danie (S234-S235).

P.1.c.021 Monoamine oxidase B density is increased in the frontal cortex of suicide victims by L.F. Callado; J. Ballesteros; A.I. Maeztu; M. Gutierrez; J.J. Meana (S235).

S.07.01 The effect of lithium on various isoforms of adenylyl cyclase by L. Mann; G. Shaltiel; E. Heldman; R.H. Belmaker; G. Agam (S175).

S.07.05 Autism candidate genes in cytogenetic regions of interest identified with a gene interaction network by W. Staal; L. Franke; J.A.S. Vorstman; R. Hochstenbach; H. Van Engeland (S176).

S.06.02 Neurocognitive functioning in OCD: an endophenotype by N. Fineberg; S.R. Chamberlain; L. Menzies; A.D. Blackwell; E.T. Bullmore; T.W. Robbins; B.J. Sahakian (S174).

S.05.03 Treatment of bipolar depression by E. Vieta; M. Garcia-Amador (S173).

S.05.04 Steroid hormone treatments by O.M. Wolkowitz; V.I. Reus; E. Epel; S. Mellon (S173-S174).

S.06.01 OCD: a multidimensional approach by E. Hollander; A. Allen; L. Rossi; D. Simeon (S174).

S.07.06 Specific effects of ecstasy on memory: a new approach to investigate neurotoxic effects in poly-substance ecstasy users by G. Jager; M.M.L. De Win; R.S. Kahn; J.M. Van Ree; W. Van den Brink; N.F. Ramsey (S176-S177).

S.07.07 The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results by O.D. Howes; A.J. Montgomery; M.C. Asselin; R.M. Murray; P.M. Grasby; P.K. McGuire (S177).

S.09.02 Suicidality in bipolar disorders by D. Souery; S. Linotte; M. Barreto; J. Mendlewicz (S180).

S.09.03 Antipsychotics in bipolar disorders by H. Grunze; F. Seemüller; A. Forsthoff; C. Born (S180).

S.08.02 Dopamine stabilising drugs by P.G. Strange (S178).

S.08.03 D2 antagonist/5-HT1A agonist interactions by A. Newman-Tancredi (S178-S179).

S.05.01 Dopaminergic agents by P. Cowen (S172).

S.04.08 Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate by X. López-Gil; Z. Babot; M. Amargós-Bosch; C. Suñol; F. Artigas; A. Adell (S172).

S.02.02 Abnormal development of brain function in ADHD and effects of methylphenidate by K. Rubia; R. Halari; A.B. Smith; M. Mohammad; E. Taylor (S166-S167).

S.02.04 Atomoxetine and ADHD by D. Purper-Ouakil (S167).

S.01.04 Psycho-education in management of schizophrenia by C. Höschl; L. Motlova (S165-S166).

Announcement (I-IV).

Author Index (S593-S610).

S.01.02 Treating schizophrenic patients with OCD and anxiety by J. Zohar; Y. Sasson; E. Yuven-Wetzler (S165).

S.04.03 Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines by L. Scott; S. Zelenin; S. Malmersjö; J.M. Kowalewski; E. Zettergren-Markus; A.C. Nairn; P. Greengard; H. Brismar; A. Aperia (S170).

S.04.05 Molecular dissection of the role of GABAB1 receptor isoforms 1a and 1b in anxiety-related behaviour by L.H. Jacobson; H.C. Neijt; B. Bettler; K. Kaupmann; J.F. Cryan (S171).

S.04.06 Fluorescence in vitro studies of human dopamine D1 and D2 receptor proteins interaction by A. Faron-Gorecka; J. Andrecka; M. Dziedzicka-Wasylewska; Z. Wasylewski (S171-S172).

S.04.01 Functional proteomic analysis of an animal model of depression combining genetic vulnerability and environmental stress by A. Mallei; R. Giambelli; V.S. Barbiero; A.A. Mathé; A. El Khoury; L. Carboni; E. Domenici; K.J. Aitchison; G. Racagni; M. Popoli (S169-S170).

S.03.02 Gene-environment interaction in depression by K. Sugden; A. Caspi; T.E. Moffitt; I.W. Craig (S168).

S.03.03 mRNA expression in post-mortem studies by J.A. Garcia-Sevilla; D. Arteta; J.J. Meana (S168-S169).

S.20.02 Neuroendocrine controls of sleep by A. Steiger; M. Kimura; M. Kluge; P. Schüssler (S193-S194).

S.20.03 Neuropeptide-monoamine interactions in normal and stress-altered sleep by V. Fabre; A. Rachalski; M. Hamon; J. Adrien (S194).

S.20.05 Genetic aspects of sleep by M. Tafti (S194-S195).

S.19.02 Mechanisms of dopaminergic dysfunction in rats with neonatal ventral hippocampus lesions by L.K. Srivastava; S.K. Bhardwaj; G. Flores; R. Quirion (S192).

S.21.03 Can propranolol prevent PTSD? by A.H. Van Stegeren (S195).

S.23.04 Immunotherapy for Alzheimer's disease by D. Schenk; S. Schroeter; M. Buttini; M. Grundman; D. Games; P. Seubert (S198).

S.24.03 Role of extrasynaptic GABA in hippocampus by B.A. Orser; L.J. Martin; V.Y. Cheng; R.P. Bonin (S198-S199).

S.23.01 Pathogenic mechanisms in Alzheimer's disease by L. Lannfelt; D. Sehlin; H. Englund; A. Lord; A.S. Johansson; L. Nilsson; F. Ekholm-Pettersson (S197).

S.21.05 The beta-3-adrenergic receptor in anxiety disorders and their treatment by J. Stemmelin; C. Cohen; G. Griebel (S195-S196).

S.22.05 Very early onset schizophrenia by J. Rapoport (S196-S197).

S.14.04 CATIE trial results by J.A. Lieberman; T.S. Stroup; J.P. McEvoy; M.S. Swartz; R. Keefe; D.O. Perkins; S. Davis; C.E. Davis; B. Lebowitz; J. Hsiao (S184-S185).

S.14.05 Metabolic side effects of antipsychotics by W.W. Fleischhacker (S185).

S.15.02 Dopamine model of OCD in rats by H. Szechtman; D. Eilam (S186).

S.10.04 Neurocognitive deficits in pathological gambling and related disorders by A.E. Goudriaan; J. Oosterlaan; E. De Beurs; W. Van den Brink (S182).

S.11.02 The ubiquitin/proteasome system in neurodegenerative disease by N.P. Dantuma; V. Menéndez-Benito; L.G.G.C. Verhoef (S183).

S.15.04 Dopaminergic challenges in social anxiety disorder by S.V. Argyropoulos; S.D. Hood; S.J.C. Davies; D.A. Hince; K. Morris; D.J. Nutt; J.P. Potokar (S186).

S.17.01 Pharmacological management of .rst episode adolescent psychosis by J. Fegert; G. Libal; P. Plener (S188-S189).

S.16.05 Blood and brain gene expressions in schizophrenia by M.T. Tsuang; S.J. Glatt; W.S. Kremen; J. Corbeil; R. Sasik; N. Khanlou; M. Han; C.C. Liew; I.P. Everall (S188).

S.16.02 Depression: the GENDEP study by U. D'Souza; K. Sugden; K.J. Aitchison; L.C. Schalkwyk; P. McGuffin; M. Pariante (S187).

S.16.03 Chronic fatigue syndrome by J.R. Kerr; R. Petty; B. Burke; D. Fear; J. Montgomery; S.C.M. Richards; M. Thomas; A.P. Smith; T.J. Harrison; P. Kellam; A.T. Holgate (S187-S188).

S.16.04 Peripheral gene expression in PTSD by A.Y. Shalev; R.H. Segman; N. Friedman; N. Kaminski; N. Sheffi; T. Goltser-Dubner (S188).

P.2.c.036 A prospective study of the incidence and predictive factors of interferon induced neuropsychiatric disorders in hepatitis C patients by P.C.A. Castellvi; C.D.Q. Díez-Quevedo; R.M.S. Martín-Santos; R.S.L. Solà; R. Navinés; J.A. Galeras (S332).

P.2.c.035 Research update from the latest STAR*D findings by M.H. Trivedi; M. Fava; A.A. Nierenberg; D. Warden; S.R. Wisniewski; A.J. Rush (S331-S332).

P.2.c.030 The COX-2 inhibitor celecoxib has therapeutic effects in major depression:results of a double-blind, placebo controlled, add-on study to reboxetine by M.J. Schwarz; S. Dehning; A. Douhe; A. Cerovecki; B. Goldstein-Müller; I. Spellmann; G. Hetzel; K. Maino; H.J. Möller; V. Arolt; M. Riedel; N. Müller (S329).

P.2.c.031 Venlafaxine/mirtazapine-combination in treatment-resistant major depression by H. Ullrich; J.L. Pach; R. Kudling; E. Klieser (S329-S330).

P.2.c.032 Influence of personality and environmental variables on the depressive response of anxiety and depressive patients by M. Vidal Millares; J. Brenlla Gonzalez; M.C. Garcia Mahia; M. Vidal Meijon; J. Mazaira Castro (S330).

P.2.d.012 Behavioural and molecular effects of the combined treatment fluoxetine plus acetylsalicylic acid in a rat model of depression by S. Alboni; G. Capone; C. Benatti; F. Tascedda; J.M.C. Blom; J. Mendlewicz; N. Brunello (S339).

P.2.d.013 TC-2216: anti-depressant effects through selective modulation of neuronal nicotinic receptors by P.M. Lippiello; M. Bencherif; G.J. Gatto; K.G. Jordan; V.M. Traina (S339-S340).

P.2.d.006 Serotonin 7 receptor antagonists as putative antidepressants with safer and faster onset of actions by C. Faure; O. Mnie-Filali; E. Gondard; A. Berod; A. Didier; P. Blier; G. Debonnel; N. Haddjeri (S336).

P.2.d.007 Proteomic analysis of hippocampus and frontal cortex in a rat model of depression with gene-environment interaction and antidepressant treatment by L. Carboni; C. Piubelli; M. Vighini; A. El Khoury; S. Gruber; W. Anderssen; A.A. Mathé; K.J. Aitchison; A. Mallei; R. Giambelli; M. Popoli; E. Domenici (S336-S337).

P.2.c.009 The incidence of antidepressant-associated mania and hypomania in major depression by W.M. Bahk; Y.S. Woo; J.H. Chae; J.H. Choi; T.Y. Jun; K.S. Kim; W. Kim (S317).

P.2.c.006 Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder by W. Chrzanowski; R. Rousseau; K. Hewett; M.D. Gee; D. Wightman; N.E. Richard; J.G. Modell; E.P. Goodale (S315-S316).

P.2.c.003 Maintenance ECT for severely depressed elderly patients by D. Mazeh; D. Paleacu; Y. Barak (S314).

P.2.c.005 Clinical pharmacokinetics of fluoxetine in depressed Parkinsonian patients on mono and combined therapy by I.K. Kovacevic; M.P. Pokrajac; B.M. Miljkovic; M.M. Mijajlovic; E.D. Dzoljic; V.K. Kostic (S315).

P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression by M. Keller; B. Yan; D. Dunner; J. Ferguson; E. Friedman; A. Gelenberg; R.M.A. Hirschfeld; J. Kocsis; S. Kornstein; C. Nemeroff; P. Ninan; A. Rothschild; A. Schatzberg; R. Shelton; M.E. Thase; M.H. Trivedi; J. Zajecka; S. Ahmed; J. Musgnung; R. Pedersen (S322-S323).

P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort by J. Tiihonen; J. Lönnqvist; K. Wahlbeck; T. Klaukka; A. Tanskanen; J. Haukka (S321).

P.2.d.017 The new antidepressant duloxetine increases BDNF mRNA and protein levels in rat frontal cortex by F. Calabrese; P.F. Maj; A. Cattaneo; M. Gennarelli; G. Racagni; R. Molteni; M.A. Riva (S342).

P.2.g.007 Influence of clock gene polymorphism on sleep-wake cycle in depressed bipolar patients: an actigraphic study by S. Dallaspezia; F. Benedetti; M. Cigala Fulgosi; B. Barbini; C. Colombo; C. Lorenzi; A. Serretti; E. Smeraldi (S361).

P.2.g.008 Serum zinc level as potential marker in recurrent depressive disorder by M. Siwek; D. Dudek; W. Datka; A. Zieba; A. Pilc; G. Nowak (S361-S362).

P.2.g.004 Severity of depression during the first year of vagus nerve stimulation in the group of non-responders by C. Frick; S. Hosten; D. Brodesser; M. Kosel; N. Axmacher; K.U. Kuehn; S. Brannan; W. Maier; T.E. Schlaepfer (S359-S360).

P.2.f.002 Plasma brain-derived neurotrophic factor and neurocognitive correlates in euthymic bipolar patients: preliminary results by V.V. Dias; S. Brissos; C. Cardoso; A.I. Carita; A. Martinez-Arán; F. Castro (S357).

P.2.g.001 Diagnostic stability in major depressive disorder as according to DSM-IV by W.M. Bahk; Y.S. Woo; J.H. Chae; T.Y. Jun; K.S. Kim (S357-S358).

P.2.g.003 The role of SSRIs in treatment of patients with irritable bowel syndrome by S.T.G. Tosic Golubovic; D.G. Gugleta; N.D. Djordjevic (S359).

P.3.a.008 Schizophrenia with catatonic features: a factor analytic study by W. Goggins; G.S. Ungvari; S.K. Leung; F.S. Ng (S368-S369).

P.3.a.007 Measuring catatonia:application of an item response theory model by G.S. Ungvari; E. Wong; S.K. Leung; W.K. Tan (S367-S368).

P.3.a.011 The heterogeneity of functional outcome measures in schizophrenia by J.L. Phillips; A.A. Ledoux; R. Westmacott; P. Boyer (S370).

P.3.a.006 Characteristics of Minnesota multiphasic personality inventory and symptom checklist 90-revision in schizophrenias with aggressive behaviour by S.H. Kang; S.H. Chung; J.Y. Jung; H.Y. Chung; M.H. Kim; H.C. Song; S.H. Kwon; M.J. Sung; Y.S. Jin; S.B. Baek (S367).

P.3.a.005 Exploring the socio-cultural components of prescription patterns in schizophrenia: a comparative study by Y.T. Xiang; Y.Z. Weng; G.S. Ungvari; C.M. Leung; W.K. Tang (S366-S367).

P.3.a.002 Elevated plasma copper/zinc ratios in patients with schizophrenia by D. Farzin; N. Mansouri; T. Yazdani (S364-S365).

P.3.a.004 Long acting risperidone in treatment of non-compliant bipolar patients by M. Cetin; C. Basoglu; S.U. Ebrinc; B. Semiz; A. Algul; M. Oguz (S365-S366).

P.2.e.001 Bipolar diathesis of unipolar treatment resistant depression by W.M. Bahk; Y.S. Woo; J.H. Chae; T.Y. Jun; K.S. Kim; W. Kim (S346-S347).

P.2.e.004 Effect of lamotrigine on concurrent electroconvulsive therapy by P. Sienaert; H. Demunter; K. Vansteelandt; J. Peuskens (S348).

P.2.e.005 Elevated urine Adam12 protein levels in lithium-treated bipolar patients by Y. Bersudsky; C. Nadri; R.H. Belmaker; G. Agam (S348-S349).

P.2.d.019 Antidepressant-like effect of the acute administration of folic acid in mice by P.S. Brocardo; J. Budni; M.P. Kaster; A.R.S. Santos; A.L.S. Rodrigues (S343).

P.2.d.020 Antidepressant-like effect of guanosine in the forced swimming test and in the tail suspension test by M.P. Kaster; K.M. Bonetti; A.R.S. Santos; A.L.S. Rodrigues (S343-S344).

P.2.e.007 Dopamine function in bipolar depressed patients by J.A. Monreal Ortiz; F. Duval; M.C. Mokrani; G. Pinault; S. Fattah; N. Chokmani; J. He; C. Champeval; J.P. Macher (S349-S350).

P.2.e.015 The efficacy and tolerability of quetiapine monotherapy in acute mania by B. Yoon; W.M. Bahk; J. Lee; S. Won; S. Lee; K. Min; D. Jon; S. Chung (S353-S354).

P.2.e.014 A new tool to detect lithium-induced glomerular nephropathy by T.J. Raedler; S. Wittke; H. Jahn; D. Schoettle; H. Mischak; K. Wiedemann (S353).

P.2.e.016 Antipsychotic treatments during acute mania with prominent aggressive behaviour by A. González-Pinto; J.A. Micó; F. Mosquera; C. González; A. Aldama; S. Barbeito; P. Vega; C. Matute; E. Vieta (S354).

P.2.e.017 Safety, tolerability and ef .cacy of rapidly-initiated quetiapine in acutely ill patients with bipolar I disorder by I. Cobo; J. Hernandez; F. Vazquez-Gutierrez; J.L. Galan; M. Tafalla (S354-S355).

P.2.e.013 Symptoms of bipolarity in patients with eating disorders by F. Rybakowski; K. Kaminska (S352-S353).

P.2.e.010 A new rat model for evaluation of efficacy and time point for onset of action for antidepressants by M.N. Jayatissa; A. Bergstroem; T. Christensen; C. Bisgaard; O. Wiborg (S351).

P.2.e.011 Aggressive behaviour during acute mania: a cross-sectional study with 173 different manic patients by F. Mosquera; S. Barbeito; E. Garcia del Moral; S. Alvarez de Eulate; P. Lopez; M. Casado; A. González-Pinto (S351-S352).

P.1.e.027 Imaging neural interactions during social information processing in schizophrenia by D. Baas; A. Aleman; N.F. Ramsey; E.H.F. De Haan; R.S. Kahn (S274).

P.1.e.026 A 3 T BOLD functional MRI study of the neural underpinnings of depression by A. Bernasconi; F. Benedetti; V. Blasi; M. Cadioli; C. Colombo; S. Dallaspezia; A. Falini; D. Radaelli; G. Scotti (S273-S274).

P.1.f.002 Treatment of bulimia nervosa with citalopram: a randomized controlled trial by C. Siano; W. Milano; C. Petrella; P. Renzi; A. Capasso (S275).

P.1.f.003 Treatment of binge eating disorder with sertraline: a randomized controlled trial by C. Siano; W. Milano; C. Petrella; P. Renzi; A. Capasso (S275).

P.1.e.024 Progesterone modulates the serotonergic influence on autobiographic memory in healthy men by C.J. Spindelegger; R. Lanzenberger; M. Mitterhauser; L.K. Mien; P. Strzelecka; W. Wadsak; U. Moser; N. Klein; A. Holik; T. Attarbaschi; J. Sacher; N. Mossaheb; T. Geiss-Granadia; K. Kletter; S. Kasper (S272).

P.1.e.020 Hippocampal serotonin-1A receptor binding correlates with cortisol plasma levels in social anxiety disorder by R. Lanzenberger; W. Wadsak; C. Spindelegger; M. Mitterhauser; N. Klein; L.K. Mien; T. Attarbaschi; N. Mossaheb; J. Sacher; A. Holik; T. Geiss-Granadia; K. Kletter; S. Kasper (S270).

P.1.e.019 Reduction of prefrontal gray matter volume in first-episode schizophrenia independent of risperidone treatment by T. Kasparek; R. Prikryl; D. Schwarz; H. Kucerova; M. Mikl; E. Ceskova; P. Krupa (S269-S270).

P.1.e.021 Neural correlates of emotional self in bipolar disorder: a BOLD functional MRI 3 T study by D. Radaelli; F. Benedetti; A. Bernasconi; V. Blasi; M. Cadioli; C. Colombo; S. Dallaspezia; A. Falini; G. Scotti; E. Smeraldi (S270-S271).

P.1.e.022 Effects of attention and emotion on face processing in depression: a functional MRI study by M.J. Desseilles; S. Schwartz; T.T. Dang-Vu; V. Sterpenich; A. Darsaud; G. Albouy; G. Vandewalle; S. Gais; M. Schabus; G. Rauchs; C. Degueldre; A. Luxen; M. Ansseau; P. Maquet (S271).

P.1.e.023 Functional MRI investigation using visual and emotional memory induction paradigms in chronic depression by A.V. Ravindran; A. Smith; C. Cameron; R. Bhatla; I. Cameron (S271-S272).

P.1.f.012 The effect of soy phytoestrogens on mental rotation by I. Riecansky; L. Pilsakova; D. Ostatnikova; F. Jagla (S280).

P.1.g.002 The orexin A plasma levels in patients with restrictive type of anorexia nervosa by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Matuszczyk (S281).

P.1.g.003 Two cases of the induction of EEG seizure during long-term rapid-rate TMS by T. Zyss; A. Zieba; D. Dudek; B. Sawicki; A. Krawczyk; M. Siwek (S281-S282).

P.1.g.004 Serum MIF as marker for immune processes in schizophrenia by L. De la Fontaine; M.J. Schwarz; M. Riedel; P. Zill; N. Müller (S282).

P.1.f.010 Event-related potentials and secondary task performance during simulated driving performance by A.E. Wester; K.B.E. Böcker; E.R. Volkerts; J.C. Verster; J.L. Kenemans (S279).

P.1.f.006 High frequency repetitive TMS over the right dorsolateral prefrontal cortex: influence on Stroop task performance by M.A. Vanderhasselt; R. De Raedt; C. Baeken; P. Clerinx; L. Leyman; H. D'haenen (S276-S277).

P.1.f.007 Alexithymia in severe obese patients by V. Marechal; G. Loas; A. Legrand; J.L. Monestes; M. Corcos (S277).

P.1.e.018 Action monitoring and psychotic ego-disturbances: a functional MRI model to link selected psychopathologic symptoms to regional physiological dysfunctions by K. Schnell; K. Heekeren; J. Daumann; T. Schnell; A. Neukirch; W. Möller-Hartmann; V. Heßelmann; E. Gouzoulis-Mayfrank (S268-S269).

P.1.e.017 Hippocampal volume in post traumatic stress disorder: effects of traumatic event and sertraline treatment by L. Bossini; M. Tavanti; S. Calossi; A. Lombardelli; N. Polizzotto; R. Galli; G. Vatti; F. Pieraccini; P. Castrogiovanni (S268).

P.1.e.001 Fusiform gyral volumes over two time points in adolescent-onset schizophrenia by A. James; S.M.C. James; D.M. Smith; C. Day (S259-S260).

P.1.e.002 Prefrontal brain function in healthy controls and patients with ADHD by A.J. Fallgatter; C.G. Baehne; A.C. Ehlis; M.M. Richter; K.P. Lesch; M.M. Plichta (S260).

P.1.e.003 DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals and schizophrenic patients by A.J. Fallgatter; M.J. Herrmann; C. Hohoff; A.C. Ehlis; T.A. Jarczok; C.M. Freitag; J. Deckert (S260).

P.1.e.004 Cingulate glutamatergic signals distinguish adult patients with ADHD from healthy controls - a magnetic resonance spectroscopy study by E. Perlov; A. Philipsen; B. Hesslinger; M. Buechert; D. Ebert; L. Tebarzt van Elst (S261).

P.1.e.012 The single-voxel proton magnetic resonance spectroscopy in recurrent depression - a pilot study by A. Silczuk; D. Dudek; M. Siwek; T. Zyss; A. Werewka-Maczuga; B. Sobiecka; J. Kozub; A. Urbanik; A. Zieba (S265).

P.1.e.014 The effects of lorazepam on extrastriatal dopamine D2/3-receptors - a positron emission tomography study with [11C]FLB 457 by H. Vilkman; J. Kajander; S. Aalto; T. Vahlberg; K. Någren; T. Allonen; E. Syvälahti; J. Hietala (S266).

P.1.e.015 Changing of dopamine transporter binding in depressed patients with anhedonia during treatment by G. Camardese; D. Di Giuda; V. Carli; A. Picello; G. Di Carlo; L. Mosca; C. Morelli; R. Rossetti; A. Giordano; P. Bria (S267).

P.1.e.011 Effect of the acute tryptophan depletion on the neural response to happy and sad faces by P. Fusar Poli; P. Allen; F. Lee; S. Surguladze; N. Tunstall; C. Fu; M. Brammer; A. Cleare; P. McGuire (S264-S265).

P.1.e.008 Hypothalamic decrease in serotonin1A receptor binding indicating disturbances in the hypothalamic-pituitary-gonadal axis in anxiety disorders by U. Moser; C.J. Spindelegger; R. Lanzenberger; L.K. Mien; M. Mitterhauser; W. Wadsak; N. Klein; T. Attarbaschi; A. Holik; N. Mossaheb; J. Sacher; K. Kletter; S. Kasper (S263).

P.1.g.005 Psychotic disorders and serotonin transporter: supporting evidences from blood cell studies by S. Baroni; G. Giannaccini; B. Dell'Osso; C. Carmassi; D. Marazziti (S282).

P.2.b.002 Depressive-like phenotype in mice lacking cannabinoid CB1 receptors by O. Valverde; E. Aso; A. Ozaita; E. Valdizán; A. Pazos; R. Maldonado (S302-S303).

P.2.b.004 Functional activity of α2-adrenoceptors in postmortem frontal cortex of depressed suicide victims by R. Diez-Alarcia; E.M. Valdizan; J. Gonzalez-Maeso; J.A. Garcia-Sevilla; A. Pazos; J.J. Meana (S303-S304).

P.2.a.035 Clinical characteristics of depressive episodes in Bipolar I and Bipolar II disorders by S. Linotte; M. Barreto; N. Van Geit; H. D'haenen; P. Vanderkelen; N. Schepers; G. Scantamburlo; W. Pitchot; M. Ansseau; K. Van der Auwera; J. Bollen; D. Souery; J. Mendlewicz (S301).

P.2.a.034 RAPSODY registry of patients with painful symptoms and observation of depression and anxiety by A. Mignon; P. Linkowski; C. Van Heeringen; M. Dramaix; S. Leyman (S300-S301).

P.2.a.030 Fatigue correlates in major depression: preliminary findings by P.P. Ferentinos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; D.G. Dikeos; C.R. Soldatos (S298-S299).

P.2.a.029 Psychopathology of sexual function: categorical or dimensional approach? by L. Bossini; M. Valdagno; N. Polizzotto; G. Capano; P. Castrogiovanni (S298).

P.2.a.031 Serotonin transporter promoter genetic characterization: possible pharmacogenetic implications of rare alleles by A. Pirovano; C. Lorenzi; P. Aartioli; E. Marino; M. Catalano; E. Smeraldi (S299-S300).

P.2.b.007 Reduced complexity of cardiovascular regulation in major depressive disorder by S. Boettger; D. Hoyer; K. Falkenhahn; M. Kaatz; K.J. Bar (S305).

P.2.b.016 Evaluation of reward processes in an animal model of depression by D.A. Slattery; A. Markou; J.F. Cryan (S310).

P.2.b.017 Biologic epistasis between SERT and BDNF: complex genetic mechanisms of depression by L.P. Pezawas; A.L. Goldman; B.A. Verchinski; V.A. Mattay; J.H. Callicott; B.S. Kolachana; R.E. Straub; M.F. Egan; A. Meyer-Lindenberg; D.R. Weinberger (S310-S311).

P.2.b.013 Neuropeptides in human cerebrospinal fluid and in brains of animal models of depression - effects of treatment by A.A. Mathé; G. Nikisch; H. Agren; P. Baumann; A. El Khoury; S.H.M. Gruber; H. Husum; P. Jiménez-Vasquez; G. Wortwein; W. Andersson; K.J. Aitchison; P. McGuffin (S308-S309).

P.2.b.010 Oxytocin, vasopression and anxiety in major depression: ago-antagonist neurohormones by G. Scantamburlo; M. Hansenne; S. Fuchs; W. Pitchot; J. Reggers; P. Marechal; E. Pinto; M. Ansseau; J.J. Legros (S306-S307).

P.2.b.011 Copper as trait marker of major depressive episode by M. Fontana; R. Squitti; S. Cesaretti; M.G. Bevacqua; M. Ventriglia; M. Ribolsi; P.L. Zuppi; P.M. Rossini (S307-S308).

P.2.a.028 Mania, hypomania, and suicidality: findings from a prospective community study by T. Bronisch; L. Schwender; M. Hoefler; H.U. Wittchen; R. Lieb (S297-S298).

P.2.a.009 Natural killer T cell patients with major depressive disorder by Y.W.J. Jeon; S.I.H. Han; E.J.P. Park (S287-S288).

P.2.a.011 A systematic review and meta-analysis on the efficacy of brief psychotherapies and pharmacotherapy in the acute treatment of depression by J. Ballesteros; I. Göemes; M.A. González-Pinto; J.R. Rueda; I. Querejeta; A. Retolaza (S288-S289).

P.2.a.006 Comparison of bifrontal and unilateral ultra-brief pulse electroconvulsive therapy for depression by P. Sienaert; K. Vansteelandt; K. Demyttenaere; J. Peuskens (S286).

P.2.a.003 Treatment resistant depression: response to prednisolone supression test by M.F. Juruena; A.S. Papadopoulos; L. Poon; S. Lightman; A.J. Cleare; C.M. Pariante (S284-S285).

P.2.a.004 Memory, attention and executive functions in melancholic versus non-melancholic depression by C. Even; C. Monier; J. Thuile; F. Rouillon; J.D. Guelfi (S285).

P.2.a.013 Chronobiological thyroid axis dysfunction in depression by M.C. Mokrani; F. Duval; J.A. Monreal Ortiz; C. Champeval; D. Maurice; J.P. Macher (S290).

P.2.a.022 Escitalopram in the treatment of obsessive-compulsive disorder by D.J. Stein; B. Tonnoir; E.W. Andersen; N. Fineberg (S295).

P.2.a.021 Depression and socio-economic status: an 8-year longitudinal population-based study by V. Lorant; C. Croux; S. Weich; D. Deliége; J. Mackenbach; M. Ansseau (S294-S295).

P.2.a.023 Maternal suicidality and risk of suicidality in offspring: findings from a community study by R. Lieb; T. Bronisch; M. Hoefler; A. Schreier; H.U. Wittchen (S295-S296).

P.2.a.024 Results of the European multi-centre study (D03) of vagus nerve stimulation in treatment-resistant depressive patients by C. Frick; S. Hosten; M. Kosel; D. Brodesser; N. Axmacher; K.U. Kuehn; S. Brannan; M. Kreft; A. Zobel; W. Maier; T.E. Schlaepfer (S296).

P.2.a.025 Predictors of response to vagus nerve stimulation by D. Brodesser; C. Frick; S. Hosten; N. Axmacher; M. Kosel; K.U. Kuehn; S. Brannan; W. Maier; T.E. Schlaepfer (S296-S297).

P.2.a.020 High cholesterol, triglycerides, and body-mass index in suicide attempters: a population-based study by J. Brunner; T. Bronisch; H. Pfister; F. Jacobi; M. Hoefler; H.U. Wittchen (S293-S294).

P.2.a.019 An actigraphic registration of depressed patients treated with chronotherapeutics by A. Pontiggia; F. Benedetti; B. Barbini; M. Cigala Fulgosi; C. Colombo; S. Dallaspezia; E. Smeraldi (S293).

P.2.a.015 Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study by D. Michelson; L.A. Adler; J.D. Amsterdam; D.L. Dunner; A.A. Nierenberg; F.W. Reimherr; A.F. Schatzberg; D.K. Kelsey; P.D. Feldman; L.R. Levine; D.W. Williams (S290-S291).

P.2.a.016 Depression in Chinese patients with Parkinson's and clinical determinants by W.K. Tang; D.M.L. Chan; H.F.K. Chiu; G.S. Ungvari; K.S. Wong; V. Mok (S291-S292).

P.2.a.018 Bupropion efficacy in major depressive disorder and alcohol dependence dual diagnosis by D. Vasile; M. Sarmache; M.L. Vasile; M.D. Gheorghe (S292-S293).